Related Experiment Video

Updated: Jul 3, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors

Xanthi N Stahtea1, Olga Ch Kousidou, Andreas E Roussidis

  • 1Department of Chemistry, Laboratory of Biochemistry, University of Patras, Patras, Greece.

Connective Tissue Research
|July 29, 2008
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) impact matrix metalloproteinases (MMPs) in solid tumors. This review covers recent advances in understanding how TKIs affect MMPs, crucial for cancer metastasis.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Cancer metastasis involves extracellular matrix (ECM) degradation, primarily mediated by matrix metalloproteinases (MMPs).
  • MMP activity is linked to tyrosine kinase receptors (RTKs), whose aberrant activity drives cancer progression.
  • Tyrosine kinase inhibitors (TKIs) target RTKs and are used in solid tumor treatment.

Purpose of the Study:

  • To review recent advances in the effects of TKIs on MMPs in solid tumors.
  • To highlight the relationship between RTK signaling and MMP expression in cancer.

Main Methods:

  • Literature review of recent studies on TKIs and MMPs.
  • Analysis of the molecular mechanisms linking RTKs, TKIs, and MMPs.

Main Results:

  • TKIs modulate the expression and activity of various MMPs in solid tumors.
  • The effects of TKIs on MMPs are diverse and depend on the specific TKI and tumor type.
  • Understanding these interactions is key to optimizing TKI-based cancer therapies.

Conclusions:

  • TKIs represent a promising therapeutic strategy by influencing MMPs involved in cancer metastasis.
  • Further research is needed to fully elucidate the complex interplay between TKIs, RTKs, and MMPs for improved cancer treatment outcomes.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...